Alnylam Pharmaceuticals target price raised to $292 from $290
ALNY•BMO raised its target price for Alnylam Pharmaceuticals to $292 from $290.
Related News
Lifetime Brands Q3 net loss more than triples to $4.2 million; net sales rise to $177.7 million
LCUT•
J.P. Morgan’s stake in DBV Technologies falls to 9.17% from 12.72%
DBVT•
Cartesian Therapeutics Q3 net loss narrows 68% to $11.47 million
RNAC•
Envoy Medical Q3 net loss narrows 32% to $5.24 million
COCH•
Zillow Group: StoneX cuts target price to $70 from $80
ZG•